Andere Sprachen Alnylam Pharmaceuticals, Inc.

Aktien

A0CBCK

US02043Q1076

ALNY

Realtime-Estimate Cboe BZX Andere Börsenplätze 20:49:21 19.04.2024			% 5 Tage	% 1. Jan.
143.9 ^USD	-0.84%		-3.26%	-24.95%

08.04.	Sektor-Update: Aktien des Gesundheitswesens am Montag vorbörslich flach bis höher	MT
08.04.	Sektor Update: Gesundheitswesen	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results	18.04.
Sector Update: Health Care Stocks Flat to Higher Premarket Monday	08.04.
Sector Update: Health Care	08.04.
RECOMENDACIONES DE LOS ANALISTAS EE.UU./UK : Chevron, Take-Two, Coinbase, Netflix, American Tower...	08.04.
Roche and Alnylam present positive results from the Phase II KARDIA-2 study of zilebesiran added to standard of care antihypertensives in patients with inadequately controlled hypertension	08.04.
Alnylam Pharmaceuticals Says Phase 2 Trial for Zilebesiran Meets Primary Endpoint	08.04.
ANALYST RECOMMENDATIONS : Chevron, Take-Two, Coinbase, Netflix, American Tower...	08.04.
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension	07.04.
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension	07.04.
Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session	20.03.
Alnylam Launches Hereditary ATTR Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease	14.03.
Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease	13.03.
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY	12.03.
L'ETF della settimana: scommettere sull'inversione di tendenza delle biotech	09.03.
ETF van de week: inzetten op de ommekeer in de biotech	08.03.
ETF de la semaine : miser sur le retournement des Biotechs	08.03.
Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure	06.03.
Alnylam annonce des résultats positifs de l’étude KARDIA-2 démontrant des réductions cliniquement significatives de la pression artérielle lorsque le zilebesiran est ajouté à des antihypertenseurs standards	05.03.
Alnylam Pharmaceuticals Says Phase 2 Study of Hypertension Drug Zilebesiran Meets Primary Endpoint	05.03.
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives	05.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Alnylam Pharmaceuticals, Inc.

Aktien

A0CBCK

US02043Q1076

ALNY

Andere Sprachen

Filter